Stay updated with breaking news from ஷரி அன்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator Good morning, and thank you for joining the GlycoMimetics call. At this time, all participants are in listen-only mode. Following management s remarks, we will hold a question-and-answer session. And at that time, the lines will be opened for you. [Operator Instructions] I would now like to turn the call over to Shari Annes of Investor Relations Group at GlycoMimetics. Please go ahead. Shari Annes Investor Relations Good morning. Today, we will review our accomplishments and financial results for the period ended March 31, 2021. We ll also update you on recent achievements. The press release we issued this morning is available on the company s website at www.glycomimetics.com under the Investors tab. This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available on the Investor Relations section of the company s website for 30 days. ....
GlycoMimetics Inc (GLYC) Q1 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Search jobs 10-Apr-2021 GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model Study demonstrates GMI-1757’s impact on immune cell infiltration and improvement of anti-PD-L1 therapeutic activity ROCKVILLE, Md. (BUSINESS WIRE) GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism to E-selectin and galectin-3, has been accepted for a poster presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21. ....